Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism

被引：31
作者：
Bu, Tong [1 ]
Sun, Ziyan [1 ]
Pan, Yi [1 ]
Deng, Xia [1 ]
Yuan, Guoyue [1 ]
机构：
[1] Jiangsu Univ, Affiliated Hosp, Dept Endocrinol, Zhenjiang 212001, Peoples R China
来源：
DIABETES & METABOLISM JOURNAL | 2024年 / 48卷 / 03期
关键词：
Adipose tissue; Glucagon-like peptide 1; Lipid metabolism; Non-alcoholic fatty liver disease; Obesity; BROWN ADIPOSE-TISSUE; GLP-1 RECEPTOR AGONIST; GCGR DUAL-AGONIST; GLUCOSE-TOLERANCE; INSULIN-SECRETION; HEPATIC STEATOSIS; DIFFERENTIATION; INCRETIN; OBESITY; CELLS;
D O I：
10.4093/dmj.2023.0277
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Glucagon-like peptide -1 (GLP-1) is a 30 -amino acid peptide hormone that is mainly expressed in the intestine and hypothalamus. In recent years, basic and clinical studies have shown that GLP-1 is closely related to lipid metabolism, and it can participate in lipid metabolism by inhibiting fat synthesis, promoting fat differentiation, enhancing cholesterol metabolism, and promoting adipose browning. GLP-1 plays a key role in the occurrence and development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, and atherosclerosis by regulating lipid metabolism. It is expected to become a new target for the treatment of metabolic disorders. The effects of GLP-1 and dual agonists on lipid metabolism also provide a more complete treatment plan for metabolic diseases. This article reviews the recent research progress of GLP-1 in lipid metabolism.
引用
收藏
页码：354 / 372
页数：20
相关论文
共 142 条
[31]   Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes [J].
El Bekay, Rajaa ;
Coin-Araguez, Leticia ;
Fernandez-Garcia, Diego ;
Oliva-Olivera, Wilfredo ;
Bernal-Lopez, Rosa ;
Clemente-Postigo, Mercedes ;
Delgado-Lista, Javier ;
Diaz-Ruiz, Alberto ;
Guzman-Ruiz, Rocio ;
Vazquez-Martinez, Rafael ;
Lhamyani, Said ;
Mar Roca-Rodriguez, Maria ;
Fernandez Veledo, Sonia ;
Vendrell, Joan ;
Malagon, Maria M. ;
Jose Tinahones, Francisco .
BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (11) :1820-1834
[32]   Are Lifestyle Therapies Effective for NAFLD Treatment? [J].
El-Agroudy, Nermeen N. ;
Kurzbach, Anica ;
Rodionov, Roman N. ;
O'Sullivan, John ;
Roden, Michael ;
Birkenfeld, Andreas L. ;
Pesta, Dominik H. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2019, 30 (10) :701-709
[33]   Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway [J].
Fang, Yunyun ;
Ji, Linlin ;
Zhu, Chaoyu ;
Xiao, Yuanyuan ;
Zhang, Jingjing ;
Lu, Junxi ;
Yin, Jun ;
Wei, Li .
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
[34]  
FIELDING CJ, 1995, J LIPID RES, V36, P211
[35]   The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect [J].
Fisman, Enrique Z. ;
Tenenbaum, Alexander .
CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
[36]   Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging [J].
Flint, Anne ;
Andersen, Grit ;
Hockings, Paul ;
Johansson, Lars ;
Morsing, Anni ;
Sundby Palle, Mads ;
Vogl, Thomas ;
Loomba, Rohit ;
Plum-Morschel, Leona .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (09) :1150-1161
[37]   Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial [J].
Frias, Juan Pablo ;
Nauck, Michael A. ;
Van, Joanna ;
Kutner, Mark E. ;
Cui, Xuewei ;
Benson, Charles ;
Urva, Shweta ;
Gimeno, Ruth E. ;
Milicevic, Zvonko ;
Robins, Deborah ;
Haupt, Axel .
LANCET, 2018, 392 (10160) :2180-2193
[38]   Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial [J].
Garvey, W. Timothy ;
Frias, Juan P. ;
Jastreboff, Ania M. ;
Roux, Carel W. le ;
Sattar, Naveed ;
Aizenberg, Diego ;
Mao, Huzhang ;
Zhang, Shuyu ;
Ahmad, Nadia N. ;
Bunck, Mathijs C. ;
Benabbad, Imane ;
Zhang, Xiaotian M. .
LANCET, 2023, 402 (10402) :613-626
[39]   Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial [J].
Gastaldelli, Amalia ;
Cusi, Kenneth ;
Fernandez Lando, Laura ;
Bray, Ross ;
Brouwers, Bram ;
Rodriguez, Angel .
LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (06) :393-406
[40]   Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes [J].
Gastaldelli, Amalia ;
Repetto, Enrico ;
Guja, Cristian ;
Hardy, Elise ;
Han, Jenny ;
Jabbour, Serge A. ;
Ferrannini, Ele .
DIABETES OBESITY & METABOLISM, 2020, 22 (03) :393-403
12345678910